Amir Avniel, Company's CEO, Recently Completed Relocation to New York
REHOVOT, Israel, and NEW YORK, August 10 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a global leader in microRNA and RNAi, announced today it has initiated the expansion of its US operations with the relocation of Amir Avniel, Chief Executive Officer, from the company's headquarters in Rehovot, Israel, to New York. The move is intended to facilitate the expected launch of Rosetta Genomics' first products, growth through partnerships and collaborations, as well as overall corporate operations in the US. The company recently announced the expansion of its diagnostic pipeline and expects the first products to be launched in 2008.
In addition, the company announces the departure Michael French, the President of its fully owned US subsidiary - 'Rosetta Genomics Inc.', whose duties will be assumed by Mr. Avniel.
"As we move closer to the planned launch of our first diagnostic products in 2008 and to ensure the growth and expansion of our technologies, it is critical to have our senior executives based in the US," said Yoav Chelouche, Rosetta Genomics' Chairman of the Board of Directors. "Amir Avniel, as our CEO, brings valuable strategic insight, in addition to a comprehensive understanding of the development of microRNA diagnostics and therapeutics. I also would like to thank Michael French for his contribution to Rosetta Genomics."
Along with Mr. Avniel, Dalia Cohen, Executive VP will be overseeing global R&D efforts from the company's New Jersey offices.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of
microRNA-based diagnostics and therapeutics. Founded in 2000, the company's
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved